Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Defining response in migraine: which endpoints are important?

John Edmeads1

  • 1Sunnybrook and Women's College Health Sciences Centre, Toronto, Canada. John.Edmeads@sw.ca

European Neurology
|May 28, 2005
PubMed
Summary

Almotriptan 12.5 mg, eletriptan 80 mg, and rizatriptan 10 mg offer the best migraine relief. Almotriptan 12.5 mg provides superior sustained pain-free relief without adverse events, meeting patient expectations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Migraines linked to intrapulmonary right-to-left shunt.

Headache·2006
Same author

Effective treatment of migraine. Terminating acute attacks, reducing their frequency.

Postgraduate medicine·2004
Same author

Is there an easy way to diagnose migraine? Challenges faced by primary care physicians include lack of time, training.

Postgraduate medicine·2004
Same author

The economic impact of migraine: an analysis of direct and indirect costs.

Headache·2002
Same author

Communication issues in migraine diagnosis.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2002

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Trials

Background:

  • Traditional migraine therapy trials focused on 2-hour pain relief.
  • Patient-centered outcomes like pain-free and sustained pain-free are now preferred.
  • Oral triptans demonstrate varying efficacy in achieving these advanced endpoints.

Purpose of the Study:

  • To compare the efficacy of oral triptans in achieving patient-desired migraine relief.
  • To evaluate sustained pain-free with no adverse events (SNAE) as a stringent endpoint.
  • To identify oral triptans with the optimal balance of efficacy and tolerability.

Main Methods:

  • Meta-analysis of oral triptan clinical trial data.
  • Comparison of efficacy for 2-hour pain relief, pain-free, and sustained pain-free endpoints.
  • Assessment of sustained pain-free with no adverse events (SNAE) rates.

Main Results:

  • Almotriptan 12.5 mg, eletriptan 80 mg, and rizatriptan 10 mg showed the highest likelihood of success for key endpoints.
  • Almotriptan 12.5 mg demonstrated the best performance in achieving sustained pain-free with no adverse events (SNAE).
  • Differences in pharmacokinetic features may contribute to varying clinical attributes among triptans.

Conclusions:

  • Almotriptan 12.5 mg offers the most favorable combination of high efficacy and good tolerability for acute migraine treatment.
  • Sustained pain-free with no adverse events (SNAE) is a valuable endpoint for assessing migraine medication effectiveness.
  • Patient expectations for rapid, complete, and lasting migraine relief are better met by specific oral triptans.

Related Experiment Videos